A Phase 3 interventional study of Evolocumab and Placebo in Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection, sponsored by Amgen. Completed at 78 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-22.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 16th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 467 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 11 in phase 3, and was the 16th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM) or placebo QM. The second part of the study is a 24-week open label extension period. During this time all participants will receive evolocumab QM.
The clinical hypothesis is that subcutaneous evolocumab QM will be well tolerated and will result in greater reduction of low density lipoprotein cholesterol (LDL-C), defined as percent change from baseline at Week 24, compared with placebo QM in human immunodeficiency virus (HIV)-positive participants with hyperlipidemia or mixed dyslipidemia.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
This study's enrollment of 467 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Browse Hyperlipidemias studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Hyperlipidemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
Drug: Evolocumab · Drug: Placebo
Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
Drug: Evolocumab
Dose of subcutaneous evolocumab QM
Also known as: EvoMab, Repatha, AMG 145
Dose of matching placebo QM
Percent Change From Baseline in LDL-C at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Baseline, Week 24
Change From Baseline in LDL-C at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Baseline, Week 24
Percentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 24
Time frame: Week 24
Percentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Baseline, Week 24
Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Baseline, Week 24
Percent Change From Baseline in Total Cholesterol (TC) at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Baseline, Week 24
Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Baseline, Week 24
Percent Change From Baseline in Triglycerides at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Baseline, Week 24
Percent Change From Baseline in HDL-C at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Bseline, Week 24
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 24
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
Time frame: Baseline, Week 24
This study was conducted at 72 centers in Australia, Belgium, Brazil, Canada, France, Greece, Italy, Poland, Portugal, Romania, South Africa, Spain, Switzerland, United Kingdom, and United States. The first participant was enrolled on 22 May 2017, and the last participant was enrolled on 23 January 2019.
| Milestone | Double-Blind Placebo/Open-Label Evolocumab | Double-Blind Evolocumab/Open-Label Evolocumab |
|---|---|---|
| Started | 157 | 310 |
| Randomized and treated | 157 | 307 |
| Completed | 155 | 303 |
| Not completed | 2 | 7 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Protocol violation | 0 | 4 |
| Milestone | Double-Blind Placebo/Open-Label Evolocumab | Double-Blind Evolocumab/Open-Label Evolocumab |
|---|---|---|
| Started | 152 | 303 |
| Received open-label study drug | 152 | 299 |
| Completed | 150 | 301 |
| Not completed | 2 | 2 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| percent change | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 24 | 1.68 ± 2.03 | -55.23 ± 1.52 |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| mg/dL | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Change From Baseline in LDL-C at Week 24 | -2.3 ± 3.1 | -77.5 ± 2.3 |
| percentage of participants | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 24 | 7.9 (4.6 to 13.4) | 73.3 (68.0 to 78.0) |
| percentage of participants | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 24 | 0.7 (0.1 to 3.7) | 72.5 (67.2 to 77.3) |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| percent change | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24 | 2.86 ± 1.74 | -48.07 ± 1.31 |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| percent change | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24 | 2.59 ± 1.50 | -45.14 ± 1.13 |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| percent change | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) at Week 24 | 2.34 ± 1.40 | -35.78 ± 1.06 |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| percent change | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24 | 10.35 ± 3.34 | -16.44 ± 2.57 |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| percent change | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 24 | 13.21 ± 3.80 | -9.25 ± 2.89 |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| percent change | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 | 2.73 ± 1.57 | 11.08 ± 1.20 |
Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)
| percent change | Double-Blind Placebo | Double-Blind Evolocumab |
|---|---|---|
| Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 24 | 12.34 ± 3.54 | -9.81 ± 2.65 |
Collected over Double-blind Treatment (DBT) Period: From randomization (for all-cause mortality) or first dose of study drug (for adverse events) to up to week 24. Open-label Extension (OLE) Period: From the start of the OLE (week 24) to end of study (week 52) for all-cause mortality; and from first dose of study drug in the OLE up to 30 days after last dose, or end of study, whichever was earlier, for adverse events.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Placebo | 0/157 (0%) | 8/157 (5.1%) | 41/157 (26.1%) |
| Double-Blind Evolocumab | 0/310 (0%) | 10/307 (3.3%) | 78/307 (25.4%) |
| Double-Blind Placebo/Open-Label Evolocumab | 0/152 (0%) | 8/152 (5.3%) | 23/152 (15.1%) |
| Double-Blind Evolocumab/Open-Label Evolocumab | 2/303 (0.7%) | 14/299 (4.7%) | 50/299 (16.7%) |
| Event | Double-Blind Placebo | Double-Blind Evolocumab | Double-Blind Placebo/Open-Label Evolocumab | Double-Blind Evolocumab/Open-Label Evolocumab |
|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/157 | 0/307 | 0/152 | 0/299 |
| Atrial fibrillationCardiac disorders | 1/157 | 0/307 | 1/152 | 0/299 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/157 | 1/307 | 1/152 | 0/299 |
| Blood loss anaemiaBlood and lymphatic system disorders | 0/157 | 0/307 | 1/152 | 0/299 |
| Gastric ulcerGastrointestinal disorders | 0/157 | 0/307 | 1/152 | 0/299 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/157 | 0/307 | 1/152 | 0/299 |
| Helicobacter gastritisInfections and infestations | 0/157 | 0/307 | 1/152 | 0/299 |
| Brain contusionInjury, poisoning and procedural complications | 0/157 | 0/307 | 1/152 | 0/299 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/157 | 0/307 | 1/152 | 0/299 |
| Basosquamous carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/157 | 0/307 | 1/152 | 0/299 |
| Event | Double-Blind Placebo | Double-Blind Evolocumab | Double-Blind Placebo/Open-Label Evolocumab | Double-Blind Evolocumab/Open-Label Evolocumab |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/157 | 11/307 | 1/152 | 8/299 |
| NasopharyngitisInfections and infestations | 2/157 | 10/307 | 6/152 | 9/299 |
| Influenza like illnessGeneral disorders | 4/157 | 12/307 | 2/152 | 3/299 |
| Back painMusculoskeletal and connective tissue disorders | 4/157 | 12/307 | 4/152 | 2/299 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/157 | 6/307 | 0/152 | 3/299 |
| Chest painGeneral disorders | 5/157 | 2/307 | 0/152 | 1/299 |
| HeadacheNervous system disorders | 5/157 | 6/307 | 3/152 | 1/299 |
| HypertensionVascular disorders | 5/157 | 0/307 | 3/152 | 4/299 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/157 | 9/307 | 1/152 | 5/299 |
| SinusitisInfections and infestations | 1/157 | 1/307 | 1/152 | 8/299 |
| Age, Continuous(years) | Double-Blind Placebo | Double-Blind Evolocumab | Total |
|---|---|---|---|
| Mean | 56.2 ± 8.0 | 56.5 ± 9.1 | 56.4 ± 8.7 |
| Sex: Female, Male(Participants) | Double-Blind Placebo | Double-Blind Evolocumab | Total |
|---|---|---|---|
| Female | 37 | 45 | 82 |
| Male | 120 | 265 | 385 |
| Ethnicity (NIH/OMB)(Participants) | Double-Blind Placebo | Double-Blind Evolocumab | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 41 | 62 |
| Not Hispanic or Latino | 136 | 269 | 405 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Double-Blind Placebo | Double-Blind Evolocumab | Total |
|---|---|---|---|
| Asian | 3 | 3 | 6 |
| Black or African American | 25 | 54 | 79 |
| White | 125 | 246 | 371 |
| Multiple Races | 1 | 0 | 1 |
| Other, Not Specified | 3 | 7 | 10 |
| Stratification Factor: Statin Use at Baseline(Participants) | Double-Blind Placebo | Double-Blind Evolocumab | Total |
|---|---|---|---|
| Statin Use = Yes | 128 | 256 | 384 |
| Statin Use = No | 29 | 54 | 83 |
| Stratification Factor: Hepatitis C Virus (HCV) Status at Baseline(Participants) | Double-Blind Placebo | Double-Blind Evolocumab | Total |
|---|---|---|---|
| HCV = Yes | 7 | 10 | 17 |
| HCV= No | 150 | 300 | 450 |
| Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL) | Double-Blind Placebo | Double-Blind Evolocumab | Total |
|---|---|---|---|
| Mean | 133.26 ± 39.97 | 133.25 ± 40.25 | 133.25 ± 40.11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from May 2017 to primary completion in Jul 2019, 25 months.
Results were first posted in Jul 2020, 1 year after primary completion.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 25 months is above that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab